AIM ImmunoTech (AIM) Cash & Equivalents (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Cash & Equivalents data on file, last reported at $5.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 547.66% year-over-year to $5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.8 million (up 547.66% YoY) and the FY2025 annual result came in at $3.0 million, up 75.49% from the prior year.
• Cash & Equivalents climbed to $5.8 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $34.5 million in Q2 2022 to a low of $476000.0 in Q2 2025.
• A 5-year average of $12.2 million and a median of $5.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 94.01% — and 2026, when it surged 547.66%.
• Tracing AIM's Cash & Equivalents over 5 years: stood at $27.1 million in 2022, then sank by 79.9% to $5.4 million in 2023, then sank by 68.73% to $1.7 million in 2024, then soared by 75.49% to $3.0 million in 2025, then jumped by 94.84% to $5.8 million in 2026.
• The last three Cash & Equivalents figures came in at $5.8 million (Q1 2026), $3.0 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.